{"entity":{"id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","aka":["NeoDREAM"],"tldr":"A phase 3 trial of Daromun in melanoma, run by Philogen S.p.A., now recruiting.","summary":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients is a phase 3 interventional study registered as NCT03567889 by Philogen S.p.A., with 186 participants planned, started 2018-09-20 and due to reach its primary completion in 2027-12. Interventions recorded: Daromun, Surgery and Adjuvant therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03567889","url":"https://clinicaltrials.gov/study/NCT03567889"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","stage-iii-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["daromun"],"companies":["philogen-s-p-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03567889","phase":"3","setting":"An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients","sponsor":"Philogen S.p.A.","started":"2018-09-20","startedType":"actual","enrolled":186,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03567889/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"drug":[{"id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/"}],"company":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/"}]}}